COMPASS give fuller results of their phase IIb research on psilocybin-assisted therapy for treatment resistant depression
COMPASS Pathways give an 'all singing/all dancing' look at their recently completed phase IIb study. In a dedicated area of their website they report "Our randomised controlled phase IIb study of psilocybin therapy in treatment-resistant depression is the largest psilocybin therapy clinical trial ever conducted, with 233 patients across 22 sites in 10 European and North American countries. This trial assessed the safety and efficacy of COMP360 psilocybin therapy in three doses: 1mg, 10mg, 25mg." Their press release gives a summary of the outcomes achieved & adverse effects encountered (which have caused some concern). The 15 picture 'slide deck' also gives a good overview of what was done and the results they got. Their Knowledge Navigator gives a more presentation glitzy look too and there are short talks by CEO George Goldsmith and employed high flyers Professors Allan Young of Kings, London and David Hellerstein of Columbia, New York. Their website also gives a nice Pipeline Overview of what their future research is likely to involve and some sense of where they've got to and where they're heading. The penultimate slide in the Slide Deck, states that they hope to "Hold an end-of-phase II meeting with FDA to discuss topline data and continue discussions around development path and phase III design – Meeting anticipated Q1 2022" and "Pending FDA meeting outcome, we anticipate advancing to phase III by Q3 2022 " as well as to "Continue expanding our pipeline of indications beyond treatment-resistant depression and post-traumatic stress disorder." COMPASS's work raises so many issues, particularly around the pluses (e.g. more funding available for big, good research studies like this) and minuses (e.g. attempts to patent substances/processes and restrict knowledge sharing) of 'for-profit' companies getting involved with psychedelics.
For more psychedelic news and research, visit the psychedelic health professional network homepage.